Clinical Trial Update: A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ASP8273 to erlotinib or gefitinib in first-line EGFR-mutant non-small cell lung cancer was terminated; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ASP8273
• ERLOTINIB (Erlotinib)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Status: TERMINATED | Results posted: 2019-02-12